Actavis to boost oncology presence in Turkey, with generic drug launches

30 November 2011

Iceland-headquartered generic drugmaker Actavis is planning to increase its presence in Turkey next year and make a real difference within the country's oncology sector. Drawing on its “expertise in affordable, high quality and technologically advanced oncology products, Actavis Turkey will launch a range of oncology medicines in 2012, along with various other new products,” said the company, the global number four in the generic sector.

Actavis chief executive and chairman Claudio Albrecht believes there is huge potential for growth within the Turkish oncology market, noting: "Actavis helps more than one million oncology patients every year around the world, with medicine that's made at our flexible, high capacity and high quality EU manufacturing sites. Actavis Turkey can offer added value in oncology, delivering great quality for patients at affordable prices."

To include generic docetaxel, irinotecan, gemcitabine, vinorelbine, fludarabine, etoposide and topotecan

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK